WO2000056325A2 - Ibuprofen-lösung - Google Patents
Ibuprofen-lösung Download PDFInfo
- Publication number
- WO2000056325A2 WO2000056325A2 PCT/EP2000/002384 EP0002384W WO0056325A2 WO 2000056325 A2 WO2000056325 A2 WO 2000056325A2 EP 0002384 W EP0002384 W EP 0002384W WO 0056325 A2 WO0056325 A2 WO 0056325A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solution
- ibuprofen
- trometamol
- solution according
- aqueous
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
Definitions
- the present invention relates to an aqueous ibuprofen solution which is particularly suitable as a medicament for intravenous infusion.
- the compound ibuprofen (2- (4-isobutylphenyl) propionic acid) belongs to the known group of non-steroidal anti-inflammatory drugs (NSAIDs).
- NSAIDs non-steroidal anti-inflammatory drugs
- ibuprofen has anti-inflammatory and analgesic properties. It is used to treat rheumatoid arthritis or other inflammatory joint diseases, soft tissue rheumatism and gout. Because of its analgesic properties, ibuprofen is also widely used as a pain reliever, for example for headaches, toothaches and menstrual cramps. Ibuprofen is easily soluble in most organic solvents, but very poorly soluble in water. As a result, it drops out immediately when a little water is added or a solution is introduced into an aqueous medium.
- DE 34 37 599 therefore proposes to dissolve ibuprofen in polyoxyethylene-polyoxypropylene polymer or in a mixture of polyalkylene glycol and a surfactant.
- a solution is stable at room temperature and no precipitation occurs when this solution is introduced into an aqueous medium, so that this solution is suitable, for example, for the oral administration of ibuprofen in soft gelatin capsules.
- EP-B-0 267 321 discloses injectable preparations of ibuprofen in combination with an amino acid to improve solubilization.
- ibuprofen injection solutions are prepared which contain lysine or meglumine in addition to the active ingredient and water.
- the pH of the injection solutions should be between 7.3 and 7.8.
- ⁇ ⁇ by Ibuprofen are Imbun and Ibuprof by et.
- Imbun ⁇ contains an ibuprofen lysine salt as a lyophilisate.
- the solution When administered, the solution must be reconstituted with water. The administration of this drug is therefore relatively complex and the reconstituted solution has a very limited shelf life.
- a solution is not suitable for intravenous infusion, in which larger volumes are generally administered. It is therefore an object of the present invention to provide an ibuprofen solution which is particularly suitable as a medicament for intravenous infusion and which, as a purely aqueous solution, is stable for as long as possible without the active substance decomposing or precipitating.
- an aqueous ibuprofen solution is stable if it contains trometamol as a buffer.
- the present invention thus relates to an aqueous ibuprofen solution which is characterized in that it contains trometamol as a buffer.
- Trometamol is the international free name for tris (hydroxymethyl) aminomethane.
- the solution according to the invention contains trometamol as a buffer, the ibuprofen being present as a trometamol salt.
- the amount of trometamol used should be sufficient to ensure dissolution of the sparingly soluble ibuprofen in water.
- the trometamol is preferably present in a small molar excess of, for example, 1.1-1.5 ol per mol of ibuprofen.
- the pH of the solution is preferably in the range from 7.8 to 8.2, it being possible to adjust this pH by adding suitable, preferably physiologically compatible, bases and / or acids.
- suitable, preferably physiologically compatible, bases and / or acids preferably physiologically compatible, bases and / or acids.
- Sodium hydroxide and hydrochloric acid are particularly suitable for setting the desired pH, 1N hydrochloric acid being preferred.
- the solution according to the invention preferably contains sodium chloride in an amount suitable for intravenous infusion.
- the solution can contain ibuprofen in an amount suitable for pharmaceutical use.
- the solution preferably contains 200-1,200 mg, for example about 400 mg or about 800 mg ibuprofen per 100 ml of the finished solution.
- the solution according to the invention is prepared by dissolving about 800 mg ibuprofen, about 605 mg trometamol, about 150 mg sodium hydroxide, about 540 mg sodium chloride and hydrochloric acid in an amount in order to adjust the pH of the solution in the range of Adjust 7.8-8.2 in water in an amount to obtain about 100 ml of solution.
- the solution according to the invention contains no organic solvents.
- the ibuprofen solution according to the invention is stable over a long period of time without the active ingredient being decomposed or precipitated.
- a solution according to the invention is stable over five years.
- Another object of the present invention is a method for producing an aqueous ibuprofen solution, wherein trometamol is dissolved in water and ibuprofen is added to this solution.
- the pH of the solution is then preferably adjusted in the range from 7.8 to 8.2.
- the ibuprofen solution according to the invention is suitable as a medicament and can be used, for example, as an intravenous infusion solution.
- the present invention thus also relates to the use of an aqueous ibuprofen solution described above as a medicament, in particular for intravenous infusion.
- the solution was prepared in a batch size of 100 l. All vessels and parts in contact with the product used for the preparation of the solution, for filtration and filling were made of materials that do not release heavy metals and do not lead to particulate contamination of the product. All equipment and machine parts in contact with the product were cleaned before use for manufacture, rinsed with demineralized water and sterilized.
- the solution thus prepared was sterile filtered and filled into 50 ml infusion bottles, which were sterilized and siliconized stoppers for infusion bottles and aluminum crimp caps were closed.
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU41060/00A AU4106000A (en) | 1999-03-19 | 2000-03-17 | Ibuprofen solution |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19912436.1 | 1999-03-19 | ||
DE19912436A DE19912436A1 (de) | 1999-03-19 | 1999-03-19 | Ibuprofen-Lösung |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000056325A2 true WO2000056325A2 (de) | 2000-09-28 |
WO2000056325A3 WO2000056325A3 (de) | 2000-12-28 |
Family
ID=7901665
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/002384 WO2000056325A2 (de) | 1999-03-19 | 2000-03-17 | Ibuprofen-lösung |
Country Status (4)
Country | Link |
---|---|
AR (1) | AR022955A1 (de) |
AU (1) | AU4106000A (de) |
DE (1) | DE19912436A1 (de) |
WO (1) | WO2000056325A2 (de) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011144677A1 (en) | 2010-05-18 | 2011-11-24 | Spain Pharma, S.A. | Pharmaceutical composition of ibuprofen for injection |
CN105055389A (zh) * | 2015-08-03 | 2015-11-18 | 北京蓝丹医药科技有限公司 | 一种用于早产儿先天性心脏病的布洛芬药物组合物 |
CN105997901A (zh) * | 2016-07-27 | 2016-10-12 | 济南东方开元医药新技术有限公司 | 小儿注射用布洛芬氨丁三醇冻干粉针组合物及制备方法 |
KR20180063901A (ko) * | 2009-03-12 | 2018-06-12 | 큠버랜드 파마슈티컬즈 인코포레이티드 | 정맥 내 투여용 이부프로펜의 투여 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10240418A1 (de) * | 2002-09-02 | 2004-03-11 | Avontec Gmbh | Formulierung zur Einschleusung von Nukleinsäuren in eukaryotische Zellen |
US8871810B2 (en) | 2009-07-15 | 2014-10-28 | Cumberland Pharmaceuticals Inc. | Treating critically ill patients with intravenous ibuprofen |
US9072710B2 (en) | 2012-03-16 | 2015-07-07 | Cumberland Pharmaceuticals Inc. | Injectable ibuprofen formulation |
CN104323988A (zh) * | 2014-11-27 | 2015-02-04 | 北京蓝丹医药科技有限公司 | 一种用于注射的右旋布洛芬药物组合物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4518608A (en) * | 1979-09-27 | 1985-05-21 | Medimpex Gyogyszerkuelkereskedelmi Vaallalat | Watersoluble derivatives of non-steroidal anti-inflammatory agents and a process for the production thereof |
WO1996014839A1 (en) * | 1994-11-15 | 1996-05-23 | Farmarc Nederland Bv | Pharmaceutical composition comprising non-steroidal anti-inflammatory drugs |
WO1999006024A1 (en) * | 1997-07-29 | 1999-02-11 | Pharmacia & Upjohn Company | Self-emulsifying formulation for lipophilic compounds |
-
1999
- 1999-03-19 DE DE19912436A patent/DE19912436A1/de not_active Withdrawn
-
2000
- 2000-03-16 AR ARP000101171A patent/AR022955A1/es unknown
- 2000-03-17 WO PCT/EP2000/002384 patent/WO2000056325A2/de active Application Filing
- 2000-03-17 AU AU41060/00A patent/AU4106000A/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4518608A (en) * | 1979-09-27 | 1985-05-21 | Medimpex Gyogyszerkuelkereskedelmi Vaallalat | Watersoluble derivatives of non-steroidal anti-inflammatory agents and a process for the production thereof |
WO1996014839A1 (en) * | 1994-11-15 | 1996-05-23 | Farmarc Nederland Bv | Pharmaceutical composition comprising non-steroidal anti-inflammatory drugs |
WO1999006024A1 (en) * | 1997-07-29 | 1999-02-11 | Pharmacia & Upjohn Company | Self-emulsifying formulation for lipophilic compounds |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180063901A (ko) * | 2009-03-12 | 2018-06-12 | 큠버랜드 파마슈티컬즈 인코포레이티드 | 정맥 내 투여용 이부프로펜의 투여 |
KR101971412B1 (ko) | 2009-03-12 | 2019-04-22 | 큠버랜드 파마슈티컬즈 인코포레이티드 | 정맥 내 투여용 이부프로펜의 투여 |
WO2011144677A1 (en) | 2010-05-18 | 2011-11-24 | Spain Pharma, S.A. | Pharmaceutical composition of ibuprofen for injection |
WO2011144766A1 (es) | 2010-05-18 | 2011-11-24 | Spain Pharma, S.A. | Composición farmacéutica de ibuprofeno para inyección |
KR101770808B1 (ko) * | 2010-05-18 | 2017-08-23 | 젠파르마 라보라토리오 에스. 엘. | 이부프로펜의 주사용 약제학적 조성물 |
CN105055389A (zh) * | 2015-08-03 | 2015-11-18 | 北京蓝丹医药科技有限公司 | 一种用于早产儿先天性心脏病的布洛芬药物组合物 |
CN105055389B (zh) * | 2015-08-03 | 2018-08-10 | 北京蓝丹医药科技有限公司 | 一种用于早产儿先天性心脏病的布洛芬药物组合物 |
CN105997901A (zh) * | 2016-07-27 | 2016-10-12 | 济南东方开元医药新技术有限公司 | 小儿注射用布洛芬氨丁三醇冻干粉针组合物及制备方法 |
Also Published As
Publication number | Publication date |
---|---|
AU4106000A (en) | 2000-10-09 |
WO2000056325A3 (de) | 2000-12-28 |
AR022955A1 (es) | 2002-09-04 |
DE19912436A1 (de) | 2000-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3240177C2 (de) | ||
DE60003803T2 (de) | Trockene formbare arzneistoffformulierung | |
US5082863A (en) | Pharmaceutical composition of florfenicol | |
EP0093999B1 (de) | Arzneimittelzubereitungen von Oxicam-Derivaten und Verfahren zu deren Herstellung | |
DE69728783T2 (de) | Verbesserte arzneimittel | |
DE60126433T2 (de) | Prozess zur herstellung von pharmazeutischen zusammensetzungen zur verwendung mit weichgelatine formulierungen | |
DE60114249T2 (de) | Pharmazeutische zusammensetzung mit 2-(4-isobutylphenyl) propionsäure | |
DE3437599A1 (de) | Ibuprofen enthaltende weichgelatinekapseln und verfahren zu ihrer herstellung | |
DE69627170T2 (de) | Nichtwässrige abführmittel für den kolon | |
CH638402A5 (de) | Verfahren zur herstellung eines pharmazeutikums fuer die einfuehrung in koerperoeffnungen. | |
DE3320582A1 (de) | Gliquidonhaltige zubereitungsformen und verfahren zu ihrer herstellung | |
DE2545973B2 (de) | Verfahren zur Herstellung eines Digoxinarzneimittels in Form von therapeutischen Einzeldosen | |
EP0185210A2 (de) | Verwendung von Dipeptidderivaten für die Herstellung von Arzneimitteln zur Behandlung von an amyotropher Lateralsklerose Erkrankten | |
WO2000056325A2 (de) | Ibuprofen-lösung | |
DE102004025324A1 (de) | Flüssige Zubereitung für die Veterinärmedizin, Verfahren zu deren Herstellung und deren Verwendung | |
DE1915798A1 (de) | Arzneimittel gegen UEbersaeuerung | |
CH647677A5 (de) | 4'-(acridinylamino)-methansulfon-anisidid enthaltende pharmazeutische zusammensetzung. | |
DE2448119A1 (de) | Pharmazeutische zubereitungen | |
DE60120630T2 (de) | Pharmazeutische Zusammensetzung enthaltend Xanthangummi | |
DE2546474A1 (de) | Injizierbares pharmazeutisches thyroxinpraeparat und verfahren zu dessen herstellung | |
DE2445400C3 (de) | Injizierbare einphasige Zubereitung und Verfahren zu ihrer Herstellung | |
DE2102889C3 (de) | Verwendung von SuIf adimidin und Pyrimethamin | |
DD279405A1 (de) | Verfahren zur herstellung eines parenteral applizierbaren analgetikums/antipyretikums | |
DE3237284C2 (de) | ||
EP0656777B1 (de) | Spritzfertige azosemid-injektionslösungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU BG BR CA CZ EE HR HU IS JP LT LV MX NO NZ PL RO SI SK TR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU BG BR CA CZ EE HR HU IS JP LT LV MX NO NZ PL RO SI SK TR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase |